Clinical Significance of BCR-ABL Fusion Gene Subtypes in Chronic Myelogenous and Acute Lymphoblastic Leukemias

Ye, Yuan-Xin; Zhou, Juan; Zhou, Yan-Hong; Zhou, Yi; Song, Xing-Bo; Wang, Jun; Lin, Li; Ying, Bin-Wu; Lu, Xiao-Jun

추천

검색

자료유형: 학술저널

저자정보: Ye, Yuan-Xin (Department of Laboratory Medicine, West China Hospital, Sichuan University) Zhou, Juan (Department of Laboratory Medicine, West China Hospital, Sichuan University) Zhou, Yan-Hong (Department of Laboratory Medicine, West China Hospital, Sichuan University) Zhou, Yi (Department of Laboratory Medicine, West China Hospital, Sichuan University) Song, Xing-Bo (Department of Laboratory Medicine, West China Hospital, Sichuan University) Wang, Jun (Department of Laboratory Medicine, West China Hospital, Sichuan University) Lin, Li (Department of Laboratory Medicine, West China Hospital, Sichuan University) Ying, Bin-Wu (Department of Laboratory Medicine, West China Hospital, Sichuan University) Lu, Xiao-Jun (Department of Laboratory Medicine, West China Hospital, Sichuan University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제22호

발행연도: 2014.1

수록면: 9,961 - 9,966 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Some reports have suggested that chronic myeloid leukemia (CML) patients have a higher prevalence of M-bcr than acute lymphoblastic leukemia (ALL) patients, which show a higher prevalence of m-bcr. However, the relationship between BCR-ABL subtypes and progression of CML and ALL remains unclear. Materials and Methods: 354 CML chronic phase (CML-CP) patients, 26 CML blastic phase (CML-BP) patients and 72 ALL patients before treatment with BCR-ABL positive were recruited for blood routine examination and bone marrow smear cytology. Some 80 CML-CP and 32 ALL patients after imatinib (IM) treatment were followed-up for BCR-ABL relative concentrations detected after treatment for 3, 6 and 9 months and 1 year. Results: Before treatment, CML-CP patients showed lower BCR-ABL relative concentrations with a higher proportion of M-bcr (42.7%) compared to CML-BP and ALL patients while ALL patients had a higher BCR-ABL relative concentration with high expression of m-bcr (51.4%). Patients with M-bcr demonstrated higher WBC counts than those with m-bcr and the mixed group and higher PLT counts were noted in the CML-CP and ALL groups. After imatinib (IM) treatment, patients with m-bcr showed higher BCR-ABL relative concentrations in both CML-CP and ALL groups. Conclusions: This study identified the BCR-ABL gene as an important factor in CML and ALL cases. The M-bcr subtype was associated more with CML while the m-bcr subtype was associated more with ALL. Patients with m-bcr seem to have a poorer response to IM in either CML or ALL patients compared to M-bcr patients.

#BCR-ABL fusion gene #chronic myeloid leukemia #acute lymphoblastic leukemia

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요